Werewolf Therapeutics, Inc.
NASDAQ:HOWLBiotechnology
+$0.06 today
- Market cap
- $50.06M
- Beta
- 0.29
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.71
Volume 1.85M
Average 5.09M
HOWL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Werewolf Therapeutics, Inc.NASDAQ: HOWL
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns positive
Q2 FY2026 net income was $3.67M, compared with -$17.98M a year earlier. Trailing-twelve-month net income was -$34.61M. Over 3 fiscal years it compounded at +4.2% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$41.66M (-31.5%) for the fiscal year ending Dec 2026, a slowdown from the -13.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3.67M+127.1% QoQ
- Last fiscal yearDec 2025
- -$60.82M-13.7% YoY
- LTMJun 2026
- -$34.61M-52.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +120.4% | -34.7% | -155.1 pp |
| 1 year | -13.7% | -31.5% | -17.8 pp |
| 3-year CAGR | +4.2% | +4.2% | +0.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (60.82M) USD
- Year-over-year change
- +13.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (60.82M) | +13.7% |
| FY2024 | 2024-12-31 | (70.52M) | -88.7% |
| FY2023 | 2023-12-31 | (37.37M) | +30.6% |
| FY2022 | 2022-12-31 | (53.81M) | -7.7% |
| FY2021 | 2021-12-31 | (49.98M) | — |
Net Income vs competitors
How HOWL compares with its peers on the latest reported figures
- HOWL's LTM Jun 2026 net income of $34.61M is the 5th largest of the 8 companies compared; the peer median is $37.19M.
- Its year-over-year change of -52.7% is the 7th highest of 8, against a peer median of -7.2%.
- Net income amounts to 164.8% of revenue for HOWL, versus a peer median of 1070.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $108.83M | -7.2% | +18.7% | — | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Jun 2026 | $34.61M | -52.7% | +4.2% | 164.8% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $4.41M | +110.8% | +18.9% | — | |
| Peer median (excluding HOWL) | $37.19M | -7.2% | -1.9% | 1070.2% | |
Competitors are the stored peer set for HOWL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.98M) | (53.81M) | (37.37M) | (70.52M) | (60.82M) |
| Depreciation & Amortization | 216K | 1.1M | 1.76M | 1.81M | 1.63M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.1M | 7.4M | 8.01M | 8.83M | 6.25M |
| Change in Working Capital | 2.28M | 2.54M | (5.89M) | 2.53M | (8.21M) |
| Accounts Receivables | 0 | (6.93M) | 5.58M | 1.35M | 0 |
| Inventory | 0 | 6.93M | 0 | 0 | 0 |
| Accounts Payables | 1.01M | (883K) | (4.34M) | 3.46M | (7.5M) |
| Other Working Capital | 1.27M | 3.42M | (7.14M) | (2.28M) | (707K) |
| Other Non-Cash Items | 519K | 2.17M | 878K | 1.16M | 856K |
| Operating Cash Flow | (42.88M) | (40.6M) | (32.61M) | (56.19M) | (60.29M) |
| Capital Expenditures | (498K) | (3.61M) | (769K) | (254K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (498K) | (3.61M) | (769K) | (254K) | 0 |
| Debt Repayment | 0 | 0 | 40M | (10M) | 0 |
| Common Stock Issued | 111.6M | 15.74M | 18.33M | 23.58M | 6.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.17M) | 166K | 100K | (496K) | 0 |
| Financing Cash Flow | 109.43M | 15.91M | 58.43M | 13.08M | 6.03M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 66.05M | (28.3M) | 25.05M | (43.36M) | (54.26M) |
| Free Cash Flow | (43.37M) | (44.21M) | (33.38M) | (56.44M) | (60.29M) |
Werewolf Therapeutics, Inc.
NASDAQ:HOWL
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.